Ipsen today announced the presentation of 14 scientific abstracts across a broad range of neurological conditions at TOXINS 2026, taking place from 14–17 January 2026 in Madrid. The presentations underscore Ipsen’s continued commitment to advancing evidence-based solutions and addressing persistent…
BridgeBio Pharma, Inc., a biopharmaceutical company focused on developing treatments for genetic diseases, announced plans to advance its long-term balance sheet strategy through a significant new financing initiative. The company disclosed that it intends to offer $550 million in aggregate…
Celltrion delivered a comprehensive update on its long-term growth strategy and next-generation therapeutic portfolio during the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco, California. The global biopharmaceutical leader outlined major advances across its innovative drug pipeline—including antibody-drug…
Sandoz Secures European Commission Approval for Ondibta® (Insulin Glargine), Reinforcing Leadership in Biosimilars and Diabetes Care Sandoz a global leader in affordable medicines, today announced that the European Commission has granted marketing authorization for Ondibta® (insulin glargine), a solution for…
Teva Pharmaceuticals Highlights AJOVY® Efficacy in Pediatric Migraine Following Publication in New England Journal of Medicine Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the New England Journal of Medicine (NEJM)…
Galderma to Showcase Advanced Neuromodulator Data at TOXINS 2026 Galderma is set to reinforce its position as a global leader in injectable aesthetics with the presentation of new clinical and scientific data from its industry-leading neuromodulator portfolio at the TOXINS…
argenx SE a global immunology company focused on transforming outcomes for patients with severe autoimmune diseases, has announced a significant regulatory milestone for its flagship therapy, VYVGART® (IV: efgartigimod alfa-fcab). The U.S. Food and Drug Administration (FDA) has accepted the…
China Approves Sanofi-Licensed Medicines Myqorzo and Redemplo, Expanding Treatment Options for Rare and Complex Diseases China’s National Medical Products Administration (NMPA) has granted regulatory approval to two innovative medicines licensed by Sanofi—Myqorzo (aficamten) and Redemplo (plozasiran). The approvals mark an…
Johnson & Johnson Launches Arbrea Breast Simulator Surgeon App for Mentor in the U.S. Johnson & Johnson has announced the U.S. launch of the Arbrea Breast Simulator Surgeon App for Mentor, a digital consultation tool designed to support plastic surgeons…
Johnson & Johnson Announces Positive Phase 3 Results for TECVAYLI® Monotherapy in Early Relapse Multiple Myeloma Johnson & Johnson a global leader in oncology innovation and multiple myeloma treatment, has announced encouraging topline results from the Phase 3 MajesTEC-9 clinical…